206 related articles for article (PubMed ID: 17974999)
1. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.
Domchek SM; Recio A; Mick R; Clark CE; Carpenter EL; Fox KR; DeMichele A; Schuchter LM; Leibowitz MS; Wexler MH; Vance BA; Beatty GL; Veloso E; Feldman MD; Vonderheide RH
Cancer Res; 2007 Nov; 67(21):10546-55. PubMed ID: 17974999
[TBL] [Abstract][Full Text] [Related]
2. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
3. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.
Mizukoshi E; Nakagawa H; Kitahara M; Yamashita T; Arai K; Sunagozaka H; Fushimi K; Kobayashi E; Kishi H; Muraguchi A; Kaneko S
Cancer Lett; 2015 Aug; 364(2):98-105. PubMed ID: 25982205
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
6. Telomerase in cancer immunotherapy.
Liu JP; Chen W; Schwarer AP; Li H
Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
[TBL] [Abstract][Full Text] [Related]
7. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB
Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
[TBL] [Abstract][Full Text] [Related]
9. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.
Danet-Desnoyers GA; Luongo JL; Bonnet DA; Domchek SM; Vonderheide RH
Exp Hematol; 2005 Nov; 33(11):1275-80. PubMed ID: 16263411
[TBL] [Abstract][Full Text] [Related]
10. Prospects and challenges of building a cancer vaccine targeting telomerase.
Vonderheide RH
Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
[TBL] [Abstract][Full Text] [Related]
11. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
[TBL] [Abstract][Full Text] [Related]
12. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
13. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
[TBL] [Abstract][Full Text] [Related]
14. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
[TBL] [Abstract][Full Text] [Related]
15. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
[TBL] [Abstract][Full Text] [Related]
16. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
18. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention.
Vonderheide RH
Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471
[TBL] [Abstract][Full Text] [Related]
19. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
Dosset M; Godet Y; Vauchy C; Beziaud L; Lone YC; Sedlik C; Liard C; Levionnois E; Clerc B; Sandoval F; Daguindau E; Wain-Hobson S; Tartour E; Langlade-Demoyen P; Borg C; Adotévi O
Clin Cancer Res; 2012 Nov; 18(22):6284-95. PubMed ID: 23032748
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
